157 related articles for article (PubMed ID: 36168114)
21. VEXAS syndrome.
Nakajima H; Kunimoto H
Int J Hematol; 2024 May; ():. PubMed ID: 38819628
[TBL] [Abstract][Full Text] [Related]
22. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
Patel N; Dulau-Florea A; Calvo KR
Semin Hematol; 2021 Oct; 58(4):204-211. PubMed ID: 34802541
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic manifestations of VEXAS syndrome.
Groarke EM; Dulau-Florea AE; Kanthi Y
Semin Hematol; 2021 Oct; 58(4):230-238. PubMed ID: 34802545
[TBL] [Abstract][Full Text] [Related]
24. VEXAS syndrome.
Grayson PC; Patel BA; Young NS
Blood; 2021 Jul; 137(26):3591-3594. PubMed ID: 33971000
[TBL] [Abstract][Full Text] [Related]
25. VEXAS syndrome in dermatology.
Afsahi V; Christensen RE; Alam M
Arch Dermatol Res; 2023 Mar; 315(2):161-164. PubMed ID: 35201420
[TBL] [Abstract][Full Text] [Related]
26. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
28. UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome.
Zakine E; Schell B; Battistella M; Vignon-Pennamen MD; Chasset F; Mahévas T; Cordoliani F; Adès L; Sébert M; Delaleu J; Jachiet M; Lepelletier C; Lemaire P; Chauvel C; Dhouaieb B; Kim R; Cassius C; Georgin-Lavialle S; Mekinian A; Bagot M; Braun T; Rousset L; Begon E; de Masson A; Fenaux P; Clappier E; Bouaziz JD
JAMA Dermatol; 2021 Nov; 157(11):1349-1354. PubMed ID: 34495287
[TBL] [Abstract][Full Text] [Related]
29. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE
Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984
[TBL] [Abstract][Full Text] [Related]
30. Clinical Challenges of Emerging Acquired Autoinflammatory Diseases, Including VEXAS Syndrome.
Kirino Y
Intern Med; 2024 Feb; ():. PubMed ID: 38296470
[TBL] [Abstract][Full Text] [Related]
31. VEXAS within the spectrum of rheumatologic disease.
Koster MJ; Warrington KJ
Semin Hematol; 2021 Oct; 58(4):218-225. PubMed ID: 34802543
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary manifestations of VEXAS syndrome with acute interstitial pneumonia and diffuse alveolar hemorrhage: a case report and literature review.
Puseljic M; Schmid J; Igrec J; Hatzl S; Scholz L; Wölfler A; Fuchsjäger M; Talakic E
ARP Rheumatol; 2024; 3(2):151-156. PubMed ID: 38956997
[TBL] [Abstract][Full Text] [Related]
33. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome.
Staels F; Betrains A; Woei-A-Jin FJSH; Boeckx N; Beckers M; Bervoets A; Willemsen M; Neerinckx B; Humblet-Baron S; Blockmans DE; Vanderschueren S; Schrijvers R
Front Immunol; 2021; 12():678927. PubMed ID: 34046042
[TBL] [Abstract][Full Text] [Related]
34. Venous and arterial thrombosis in patients with VEXAS syndrome.
Kusne Y; Ghorbanzadeh A; Dulau-Florea A; Shalhoub R; Alcedo PE; Nghiem K; Ferrada MA; Hines A; Quinn KA; Panicker SR; Ombrello AK; Reichard K; Darden I; Goodspeed W; Durrani J; Wilson L; Olteanu H; Lasho T; Kastner DL; Warrington KJ; Mangaonkar A; Go RS; Braylan RC; Beck DB; Patnaik MM; Young NS; Calvo KR; Casanegra AI; Grayson PC; Koster MJ; Wu CO; Kanthi Y; Patel BA; Houghton DE; Groarke EM
Blood; 2024 May; 143(21):2190-2200. PubMed ID: 38306657
[TBL] [Abstract][Full Text] [Related]
35. Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome in the intensive care unit: a case report.
Belicard F; Belhomme N; Bouzy S; Saillard C; Nedelec F; Mear JB; Ardois S; Pastoret C; Reizine F; Camus C; Painvin B
J Med Case Rep; 2023 Jul; 17(1):314. PubMed ID: 37480098
[TBL] [Abstract][Full Text] [Related]
36. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Huang H; Zhang W; Cai W; Liu J; Wang H; Qin T; Xu Z; Li B; Qu S; Pan L; Huang G; Gale RP; Xiao Z
Exp Hematol Oncol; 2021 Mar; 10(1):23. PubMed ID: 33741056
[TBL] [Abstract][Full Text] [Related]
37. Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.
Matsumoto H; Fujita Y; Fukatsu M; Ikezoe T; Yokose K; Asano T; Tsuchida N; Maeda A; Yoshida S; Hashimoto H; Temmoku J; Matsuoka N; Yashiro-Furuya M; Sato S; Murakami M; Sato H; Sakuma C; Kawashima K; Shakespear N; Uchiyama Y; Watanabe H; Kirino Y; Matsumoto N; Migita K
Front Immunol; 2022; 13():897722. PubMed ID: 35757758
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors for the treatment of VEXAS syndrome.
Bindoli S; Baggio C; Doria A; Bertoldo E; Sfriso P
Exp Biol Med (Maywood); 2023 May; 248(5):394-398. PubMed ID: 37243340
[TBL] [Abstract][Full Text] [Related]
39. VEXAS syndrome: An update.
Khitri MY; Hadjadj J; Mekinian A; Jachiet V
Joint Bone Spine; 2024 Feb; 91(4):105700. PubMed ID: 38307404
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow reinvestigation leading to the diagnosis of VEXAS syndrome.
Strasser B; Kranewitter W; Hofer H; Haushofer A
Lab Med; 2024 Mar; ():. PubMed ID: 38530637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
